- Name Timothy Ward
- Institute Cancer Research UK Manchester Institute
- Tool name: K562 AZQR Cell Line
- Tool type: Cell Lines
- Tool sub-type: Continuous
- Parental cell line: K562
- Organism: Human
- Tissue: Lymphatic Tissue
- Cancer type: Human caucasian chronic myelogenous leukemia (drug resistant)
- Disease: Cancer
- Growth properties: Suspension
- Model: Tumour line
- Conditional: No
- Description: The cells have been shown to contain decreased levels of glutathione and superoxoid dismutase. They are cross-resistant to adriamycin, mitzolamide, MMNG and mitmycin. Cells should be challenged with AZQ at every 4th passage at a minimum density of 100,000 cells/ml. It is recommended to cultivate the cells without drug on resuscitation.
- Research area: Cancer; Drug Discovery & Development
- Production details: The drug resistant cell line K562 AZQ was developed from the parent K562 cell line by treatment with AZQ C215-bis (carboethoxyamino)-3, 6-diazitinyl 1;4 (benzoquinone).
- Cellosaurus ID: CVCL_2967
- For Research Use Only
- Format: Frozen
- Growth medium: Subculture Routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37Â°C.Culture Medium: RPMI 1640 + 10% Foetal Bovine Serum (FBS) + 2mM Glutamine. Challenge with 1 mM AZQ every 4th passage.
- Shipping conditions: Dry ice
- • Ward et al. 1995. Biochem Pharmacol. 50(4):459-64. PMID: 7646550.
- • Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones.